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Abstract
Drug efflux transporters in the placenta can significantly influence the materno-fetal transfer of a diverse array of drugs and
other xenobiotics. To determine if clinically important drug efflux transporter expression is altered in pregnancies
complicated by gestational diabetes mellitus (GDM-I) or type 1 diabetes mellitus (T1DM-I), we compared the expression of
multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2) and the breast cancer resistance
protein (BCRP) via western blotting and quantitative real-time polymerase chain reaction in samples obtained from insulin-
managed diabetic pregnancies to healthy term-matched controls. At the level of mRNA, we found significantly increased
expression of MDR1 in the GDM-I group compared to both the T1DM-I (p,0.01) and control groups (p,0.05). Significant
changes in the placental protein expression of MDR1, MRP2, and BCRP were not detected (p.0.05). Interestingly, there was
a significant, positive correlation observed between plasma hemoglobin A1c levels (a retrospective marker of glycemic
control) and both BCRP protein expression (r=0.45, p,0.05) and BCRP mRNA expression (r=0.58, p,0.01) in the insulin-
managed DM groups. Collectively, the data suggest that the expression of placental efflux transporters is not altered in
pregnancies complicated by diabetes when hyperglycemia is managed; however, given the relationship between BCRP
expression and plasma hemoglobin A1c levels it is plausible that their expression could change in poorly managed diabetes.
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Introduction
Over 220 million people worldwide are diagnosed with diabetes
and rising prevalence is reported in nearly all surveyed populations
[1,2]. Accordingly, the percentage of pregnancies affected by pre-
existing type 1 (T1DM) and type 2 diabetes mellitus (T2DM) or by
diabetes that develops during the second and third trimesters of
pregnancy, called gestational diabetes mellitus (GDM), is also on
the rise. In the context of pharmacokinetic variation, it is known
that diabetes alters drug-disposition mechanisms in non-pregnant
subjects, as reviewed by Gwilt and colleagues [3], but the impact
of diabetes on drug disposition in pregnancy has not been
thoroughly evaluated. Atypical drug disposition in pregnancy has
implications for both maternal and fetal health, as the effectiveness
of clinically important therapeutics may be compromised.
Drugs, xenobiotics, and their metabolites encounter a variety of
epithelial and endothelial barriers as they make their way to their
site(s) of action and elimination. To circumvent these barriers, they
are required to cross cell membranes. Multidrug resistance protein
(MDR) 1 (P-glycoprotein; Gene: ABCB1), multidrug resistance-
associated protein 2 (MRP2; Gene: ABCC2) and the breast cancer
resistance protein (BCRP; Gene: ABCG2) are abundantly
expressed ATP-binding cassette (ABC) drug efflux transporters
found in the apical localization of the placental syncytiotropho-
blast layer (Fig. 1). Here they limit the materno-fetal transfer of
a diverse array of drug substrates by the ATP-driven efflux of
substrates from the fetal compartment into the maternal
circulation [4,5,6]. The importance of these transporters in
determining fetal xenobiotic exposure has been well-established
in placental cell lines and placental primary cultures [7], in
mutant/knockout mice [8,9,10,11], and in ex vivo placental
perfusion models [12,13,14]. In one such study, relative to
controls, pregnant Mdr1 gene knockout mice (Mdr1
-/- mice)
treated with the Mdr1/Bcrp-specific inhibitor GF120918 exhib-
ited twice the fetal penetration of the Mdr1/Bcrp substrate
topotecan, a DNA topoisomerase inhibitor and potent antineo-
plastic agent [6]. Whereas lack of or decreased expression can lead
to increased exposure to xenobiotics, over expression may result in
decreased exposure. This may result in clinical consequences when
treating fetal illness (e.g. fetal arrhythmias with digoxin, a MDR1
substrate [15]) or by limiting the maternal-fetal passage of
therapeutics believed to contribute to the prevention of vertical
disease transmission (e.g. highly active antiretroviral therapy in
antenatal HIV infection).
We have previously demonstrated that placental MDR1, MRP2
and BCRP mRNA expression is elevated in rat dams with
streptozotocin-induced gestational diabetes mellitus (GDM) but
nearly normal in rat dams with streptozotocin-induced GDM
whose blood glucose was normalized following insulin treatment
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35027[16]. In the aforementioned study, relative to controls, fetal
exposure to the MDR1 substrate lopinavir, a commonly used HIV
protease inhibitor, was found to be dramatically lower in rat dams
with streptozotocin-induced GDM [16]. These profound results
and the increasing prevalence of diabetes mellitus in pregnancy
prompted us to study the impact of GDM and T1DM on placental
transporter expression.
Therefore, in the present study, we examined mRNA and
protein expression of MDR1, MRP2 and BCRP in placentas from
pregnancies complicated by type 1 diabetes mellitus (T1DM-I) or
gestational diabetes mellitus (GDM-I). All available placental
samples were obtained from patients whose glycemia was
managed with insulin treatment. We hypothesized that placental
drug efflux transporter expression may be altered in individuals
who have diabetes, but could be normalized to levels found in
healthy term controls in patients with well-managed diabetes
based on our previous preclinical findings in pregnant animal
models of non-treated and insulin-treated diabetes mellitus [16].
Methods
Sample Acqu1isition
Thirty-five human specimens from pregnancies meeting our
inclusion/exclusion criteria (Table 1) were obtained by the
Research Centre for Women’s and Infants’ Health (RCWIH)
BioBank program of Mount Sinai Hospital, in accordance with the
policies of the Mount Sinai Hospital Research Ethics Board.
Sample acquisition and aspects of placental processing and
measurement are extensively described on the RCWIH BioBank’s
website: http://biobank.lunenfeld.ca. Briefly, immediately after
delivery, large tissue cores through the full thickness of the
placenta were obtained in each quadrant, avoiding chorionic plate
tissue and areas with obvious evidence of thrombosis or other
abnormalities. Samples were snap-frozen in liquid nitrogen and
stored at 280uC until use. All clinical data that was extracted from
patient charts and collected by the RCWIH BioBank program of
Mount Sinai Hospital was made available to this study. In
accordance with the recommendations of Nelson and Burton [17],
supplemental tables describing key patient variables were
compiled (See data S1). Extensive chart review was completed to
ensure that all patients met our inclusion/exclusion criteria and
that any medications patients were taking were recorded. Samples
included in this study reflect total RCWIH BioBank availability
between September 2006 and February 2012: 8 T1DM-I samples,
13 GDM-I samples, and 14 randomly selected term controls.
Hemoglobin A1c Level Determination
HbA1c levels were determined by GLP certified laboratories
using the Roche Cobas Integra Clinical Chemistry System. In this
assay, all hemoglobin variants which are glycated at the b-chain
N-terminus and which have antibody-recognizable regions
identical to that of HbA1c are determined. HbA1c is presented
as a percentage of total hemoglobin (% HbA1c).
RNA Extraction and cDNA Synthesis
Total RNA was extracted from 60 mg of placental tissue using
the TRIzol method (Invitrogen, Carlsbad, CA) and subjected to
qualitative and quantitative measurements (A260/280.1.90 and
A260/320.1.60) using a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Waltham, MA). 4 mg of total extracted RNA was
reverse transcribed to cDNA using the Maxima First Strand
cDNA Synthesis Kit for RT-qPCR (MBI Fermentas, Hanover,
MD), all according to the manufacturer’s instructions. Briefly,
4 mL of reaction mix (containing reaction buffer, dNTPs, oligo
and random hexamer primers), 2 mL of Maxima Enzyme mix
containing Maxima Reverse Transcriptase and RiboLock RNase
inhibitor, sample RNA, and nuclease-free H2O were added and
centrifuged. Samples were then reverse-transcribed in an Eppen-
dorf Thermocycler (Eppendorf AG, Hamburg, Germany) with the
following thermocycling parameters: 10 min at 25uC, 30 min at
50uC, and 5 min at 85uC.
Real-Time Quantitative Polymerase Chain Reaction
(qPCR)
MDR1 (ABCB1), MRP2 (ABCC2), and BCRP (ABCG2)
mRNA expression levels in placentae from T1DM-I, GDM-I,
and term-matched controls were determined by real-time
quantitative reverse-transcriptase polymerase chain reaction.
RT-qPCR was performed on cDNA using LightCycler technology
with SYBR Green I fluorescence detection (Roche Diagnostics,
Montreal, QC). PCR oligonucleotides were synthesized at The
Hospital for Sick Children (DNA Synthesis Centre, Toronto, ON)
and were designed to span adjacent exon-exon junctions to
eliminate the amplification of genomic DNA. Primer sequences
were as follow: 59-ACCAGATAAAAGAGAGGTGCAACGG-39
(MDR1-F), 59-TCCCGGCCCGGATTGACTGA-39 (MDR1-R),
59-AGCAGCCATAGAGCTGGCCCTT-39 (MRP2-F), 59-AG-
CAAAACCAGGAGCCATGTGCC-39 (MRP2-R), 59-AG-
CAGCTCTTCGGCTTGCAACA-39 (BCRP-F), 59-
GTTCCAACCTTGGAGTCTGCCACT-39 (BCRP-R), 59-
AGCCTCGCCTTTGCCGATCC-39 (b-actin-F), and 59-
TTGCACATGCCGGAGCCGTT-39 (b-actin-R). Briefly, 2 mL
of cDNA was added to 18 mL of reaction mix containing 4 mLo f
Roche SYBR green, 100pmol of forward and reverse qPCR
primers, and nuclease-free H2O. Sequences were amplified using
the following thermocycling parameters: 1 cycle of 10 min at
95uC, 50 cycles (6 seconds at 95uC, 5 seconds at 55uC, and 6
seconds at 72uC), followed by a continuous 150-second melt curve
from 65–99uC. A melt-curve was used after amplification to
ensure primer specificity such that all samples exhibited a single
amplicon. No template control samples were also run to confirm
Figure 1. Localization of MDR1, MRP2, and BCRP in placenta.
The syncytiotrophoblast (S) layer of the placenta is comprised of
multinucleated (N) cells that contain a number of apically-localized
transport proteins that contribute to the function of the placental
barrier, including MDR1, MRP2, and BCRP.
doi:10.1371/journal.pone.0035027.g001
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genomic DNA.
Expression levels of transporters and b-actin mRNA as Cq (the
point at which gene of interest and reference gene could be
quantified) were quantified using the Roche LightCycler II
software (Ver. 3.5) configured with the Roche LightCycler II
real-time qPCR instrument (Roche Diagnostics GmbH, Ham-
burg, Germany). Gene-of-interest expression was normalized to b-
actin (ACTB) mRNA expression, using the efficiency-corrected
DCt method and presented as a gene-to-b-actin ratio. The
efficiency-corrected DCt method was used because there were
slight differences in the efficiencies of our primer sets as
determined by standard curve analysis of serially-diluted calibrator
cDNA. Gene-to-b-actin ratios were then converted to percentages
of a calibrator sample and presented as such in figure 2.
Western Blotting
300 mg of placental samples were homogenized using a motor-
ized pestle in radioimmunoprecipitation assay (RIPA) buffer,
containing freshly added dithiothrietol (1 mM; DTT; Sigma-
Aldrich, Oakville, ON), phenylmethylsulfonyl fluoride (0.5 mM;
PMSF; BioShop Canada Inc., Burlington, ON) and 1X protease
inhibitor cocktail (Sigma-Aldrich, Oakville, ON). Homogenates
were then incubated on ice for 30 min with brief vortex mixing at
15 min and subsequently centrifuged at 18,000 g for 15 min. For
each sample, the supernatant was isolated and subjected to
a Bradford assay [18]. Samples containing 60 mg of protein in
Laemmli sample loading buffer were heated at 36uC for 20 min
and then separated via 8% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and transferred to polyvinylidene difluoride
(PVDF) membranes (Bio-Rad Laboratories Canada, Ltd., Mis-
sissauga, ON). PVDF membranes were blocked in 5% non-fat dry
milk in TBST and incubated with an anti-MDR1 mouse
monoclonal antibody (C219 clone, 1:500, ID Labs Biotechnology,
Inc., London, ON), anti-MRP2 mouse monoclonal antibody (M2
III-6 clone, 1:100, Abcam, Inc., Cambridge, MA) or anti-BCRP
rat monoclonal antibody (BXP-53 clone, 1:50, Abcam, Inc.,
Cambridge, MA) in 2% non-fat milk TBST. These MDR1,
MRP2, and BCRP antibodies are commercially available and
produce distinct, quantifiable bands when used as described in the
next paragraph (data S2). Furthermore, they have previously been
utilized to analyze the expression of transporters in both human
and animal tissues [19,20,21].
Table 1. Inclusion/exclusion criteria.
Group Inclusion criteria Exclusion criteria
Term control N .37 weeks + 0 days N Pertaining to diabetes status:
o T1DM, T2DM, or GDM
N Other:
o Hypothyroidism or hyperthyroidism
o Cushing’s disease
o Essential hypertension
o Pregnancy-induced hypertension
o Arrhythmias
o Rheumatic fever
o Thalassemia
o Sickle cell anemia
o von Willebrand disease
o Immunothrombocytopenia
o Multiple sclerosis
o Epilepsy
o Bipolar (medicated)
o Systemic lupus erythematosus
o Antiphospholipid antibody syndrome
o Rheumatoid arthritis
o Inflammatory bowel disease
o Irritable bowel syndrome
o Chorioamnionitis
o Group B streptococcus
o Sexually transmitted infections
o Urinary tract infections
o H1N1 during pregnancy
o Gallstones or kidney stones
o Renal or liver disease
o Cholestasis of pregnancy
o Placenta increta/percreta
o Placental abruption
o Pelvic inflammatory disease
o Recovered from cancer
o Smoking during pregnancy
T1DM-I N T1DM (insulin-managed)
N .37 weeks + 0 days
N Pertaining to diabetes status:
o T2DM
N Other:
o Same as term control group
GDM-I N GDM (insulin-managed)
N .37 weeks + 0 days
N Pertaining to diabetes status:
o T1DM, T2DM, GDM (diet-managed)
N Other:
o Same as term control group
doi:10.1371/journal.pone.0035027.t001
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with a horseradish peroxidase-labeled secondary antibody (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA) in 2% non-
fat milk TBST. Following a series of washes with TBST,
immunoreactive proteins were detected in membranes using
ECL Plus chemiluminescence (Amersham Biosciences, Baie
d’Urfe ´, QC). The optical density (OD) of each band was
determined using ImageJ for Macintosh (version 1.44o) software.
To confirm equivalent protein loading, immunodetection using an
anti-b-actin monoclonal antibody was employed (AC-15,
1:30,000, Sigma-Aldrich, Oakville, ON) so that the OD of
MDR1, MRP2 and BCRP could be normalized internally to b-
actin. To correct for gel-to-gel variability, a calibrator sample was
run in each gel. Protein-of-interest/b-actin ratios for each blot
were converted to percentages of that blot’s calibrator sample’s
ratio.
Statistics
Patient and transporter expression data were analyzed using
GraphPad Prism 5.0 for Macintosh (GraphPad Software, Inc., San
Diego, CA). Patient clinical characteristics were all analyzed using
the ANOVA followed by the post hoc Bonferroni’s multiple
comparison test to assess for subgroup differences. Western blot
and quantitative real-time PCR results are reported as protein (or
gene)-of-interest/b-actin ratio as % calibrator for each placental
group. Protein (or gene)-of-interest/b-actin ratio as % calibrators
were compared by ANOVA followed by the post hoc Dunn’s or
Bonferroni’s multiple comparison test to assess for subgroup
changes in protein and mRNA expression. Spearman coefficient
analysis was used to determine the correlation between the levels
of mRNA and protein expression of MDR1, MRP2, and BCRP
transporters to HbA1c levels. Power analysis was performed using
G*Power 3.1 for Macintosh [22]. Levels of significance for
statistical analyses were set at or below a=0.05, indicated as
follows: */#,p ,0.05 and **/##,p ,0.01. All results are
presented as mean6S.D.
Results and Discussion
There are a number of short- and long-term maternal and fetal
consequences of unmanaged, or poorly managed, diabetes in
pregnancy. Throughout gestation, pregnant women with diabetes
Figure 2. Placental ABC efflux transporter expression in pregnancies complicated by insulin-managed diabetes. A, MDR1 (ABCB1). B,
MRP2 (ABCC2). C, BCRP (ABCG2). Boxes represent quartiles enclosing 50% of the data and the whiskers at either end extend to the 25
th and 75
th
quartiles. The median is marked by a line, the mean is marked by an ‘‘+’’ and outliers are marked by a ‘‘N’’ outside the 25
th and 75
th quartiles. The
‘‘Combined’’ group presents data from all patients (n=33) and was not included in statistical analyses. D, Spearman correlation analysis of the
relationship between HbA1c levels (%) and BCRP mRNA expression in diabetic pregnancies (p,0.01).
doi:10.1371/journal.pone.0035027.g002
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triad of diabetes symptoms). Pregnant women with diabetes can
also experience hyperlipidemia [23,24,25,26] and reduced weight
gain [27]. For the fetus, in the prenatal period, there is increased
production of fetal insulin, which leads to increased storage of
excess glucose as fetal adipose tissue and the development of
macrosomia [28,29]. Placental enlargement is also a feature of
pregnancies affected by diabetes [30,31,32,33,34,35,36]. With
T1DM, shorter gestational periods have been reported [33]. The
long-term consequences of unmanaged, or poorly managed,
diabetes in pregnancy revolve primarily around the risk of future
metabolic disease in both mother, when GDM, and child
[28,29,37,38]. These consequences, both short- and long-term,
are believed to be directly related to the degree of maternal
hyperglycemia (i.e., the severity of maternal disease across
gestation).
Patient data for the groups with diabetes indicate that only the
T1DM-I group displayed characteristics of poorly managed
diabetic pregnancy (Table 2; data S1). In the T1DM-I group,
gestation was significantly shorter (p,0.01) and there was a trend
toward larger placental volume (p=0.07). Despite T1DM mothers
having a shorter gestational age, their neonates actually trended
towards a higher birth weight (Table 2). It is possible that neonates
in this condition would have become significantly heavier had
their gestations been of equivalent duration. Nonetheless, the
absence of significant differences in neonatal birth weight,
particularly given the strong correlation that exists between
neonatal birth weight and maternal blood glucose concentrations,
could signify adequate glycemic control in this study’s T1DM-I
and GDM-I subgroups [39,40].
Following a high fasting blood glucose reading or high oral
glucose tolerance test, women are diagnosed with diabetes and
their HbA1c levels monitored over time to track glyemic control.
In proportion to blood concentrations, glucose is able to react with
normal hemoglobin (HbA0) in red blood cells to produce HbA1c.
HbA1c concentrations, therefore, reflect average blood glucose
concentrations over the previous 3–4 months, which is the
approximate lifespan of red blood cells [41]. Murphy and
colleagues found that maintaining lower HbA1c levels in the
third trimester of pregnancy by way of continuous blood glucose
monitoring was associated with decreasing risk of fetal macrosomia
[42], which is thought to be the result of prolonged periods of
glucose mismanagement. Mean HbA1c values for both diabetic
groups fell within acceptable ranges for managed diabetes (i.e.,
#6.5% HbA1c), which is again supportive of proper glycemic
control at the group level. At the individual level, though, 4
T1DM-I group members and 2 GDM-I group members exhibited
HbA1c levels that exceeded 6.5%, which indicates some degree of
mismanagement within the DM groups. Clinical data for
a measure of glycemic control, glycosylated hemoglobin (HbA1c),
was available only for the diabetic groups due to the inappropri-
ateness of routinely conducting this test in healthy term-control
populations.
Very little attention has been paid to drug disposition
mechanisms, such as placental transporter expression and/or
function, in pregnancies affected by T1DM or GDM. In this
study, average placental MRP2 and BCRP mRNA and protein
expression in the T1DM-I and GDM-I groups was not statistically
different from controls (Fig. 2B, 3B, 2C, 3C). Placental MDR1
mRNA expression was significantly higher in the GDM-I group,
relative to controls, but this did not translate into significantly
higher MDR1 protein expression (Fig. 2A and 3A). Normal
expression in these insulin-managed groups, with the exception of
MDR1 mRNA in GDM-I, is consistent with our observations in
insulin-managed rat dams with streptozotocin-induced GDM [16].
Interestingly, when examining individual rather than mean
levels, plasma HbA1c levels were found to positively correlate with
BCRP mRNA (r=0.58; p,0.01; Fig. 2D) and protein (r=0.45;
p,0.05; Fig. 3D) expression in both insulin-managed diabetes
groups. Significant correlations were not seen with MDR1 and
MRP2 mRNA or protein expression. The strong relationship
between glycemic control and BCRP expression in pregnancies
complicated by insulin-managed diabetes may indicate that
placental BCRP is particularly responsive to periods of hypergly-
cemia. Future mechanistic studies will follow up on this hypothesis.
Table 2. Clinical data.
Characteristic
Control
(n=14) T1DM (n=8) GDM (n=13)
Age (years) 32643 3 633 5 64
Ethnicity
Caucasian 11 (79) 6 (75) 7 (54)
Asian 3 (21) 0 (0) 1 (8)
Black 0 (0) 0 (0) 2 (15)
Other 0 (0) 2 (25) 3 (23)
BMI 23.264.5 25.963.9 2966.6*
Duration of diabetes (years) N/A 1769 ,1
HbA1c (%)
a N/A 6.460.6 660.8
Therapeutics used
b (#)2 614 623 61
Gravidity (#) 2.361.1 3.262.2 2.260.9
Parity (#) 1.860.8 2.161.2 1.860.7
Gravidity/parity ratio 1.360.6 1.660.4 1.260.3
GBS status
Positive 0 (0) 0 (0) 0 (0)
Negative 14 (100) 8 (100) 8 (69)
Unknown 0 (0) 0 (0) 4 (31)
Mode of delivery
Vaginal 5 (36) 4 (50) 2 (15)
C-section 9 (64) 4 (50) 11 (85)
Rupture of membranes
SROM 3 (21) 2 (25) 1 (8)
AROM 11 (79) 6 (75) 12 (92)
Gestational age (days) 27567 26666** 27165
Neonatal birth weight (g) 34816417 37056542 33016404
Neonatal sex
Male 7 (50) 6 (75) 5 (38)
Female 7 (50) 2 (25) 8 (62)
Placental weight
c (g) 6086127 6666101 6616175
Placental volume
d (cm
3) 6816174 9776381 7666283
Neonate:placenta weight ratio 5.960.8 5.460.9 5.261.1
Statistical results are presented as mean6SD. All other results are presented as
[n (%)].
*, Significantly different from term controls (*, p,0.05; **, p,0.01). N/A, not
applicable or not available.
aHbA1c values were measured in the 2
nd and/or 3
rd trimester and are presented
as group means, based on 1–5 individual measurements.
bIncludes drugs, vaccines and vitamin supplements.
cWet, untrimmed weight.
doi:10.1371/journal.pone.0035027.t002
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sulfate conjugates, antineoplastics, antibiotics, antiretrovirals, oral
hypoglycemic agents, statins, natural health products, and several
dietary carcinogens [43,44,45,46,47,48].
The concept of glucose mismanagement during insulin-
managed GDM or T1DM pregnancies has not been well
investigated in the literature. To treat diabetes mellitus in
pregnancy, exogenous insulin injections are typically self-admin-
istered and supplementary insulin tables are used to adjust dosages
to meet specific blood glucose goals of individual patients across
gestation. Given that many of the women in our study were
experiencing diabetes for the first time (i.e. GDM) and that glucose
levels and demands can change rapidly over gestation, the regular
administration of parenteral insulin in combination may have
resulted in patient failures in management of hyperglycemia.
Clinical statistics for diabetes mismanagement are limited in
pregnancy; however, reports in the literature illustrate that the
percentage of patients with GDM who do not achieve their
specific blood glucose goals falls between 20–30% [49,50]. In the
context of our study, we observed 6 of the 21 women in the
combined diabetic groups with HbA1c levels that exceeded 6.5%.
This equates to glucose mismanagement of approximately 28% in
our clinical population, which is in agreement with the range
proposed from Langer’s more powerful studies. Unfortunately, our
study lacked statistical power to determine whether women with
higher HbA1c levels, who are presumed to have had poorer
glycemic control, also had statistically higher levels of BCRP
mRNA and protein.
Using animal model-derived effect sizes of 0.78 for Mdr1 (200%
mRNA increase, CV=42%), 0.53 for Mrp2 (456% mRNA
increase, CV=120%) and 0.67 for Bcrp (230% mRNA increase,
CV=53%), a total sample size of 39 patients (13/group) would be
required to achieve power $ 0.8 in an F test for all of the
transporters examined in this study. The actual power achieved for
MDR1, MRP2 and BCRP analyses in this study, based on these
animal model-derived effect sizes, was 0.98, 0.77 and 0.93,
respectively (group sizes were averaged for these post hoc power
calculations); however, clinical effect sizes are often smaller than
effect sizes in animal models. Because placental transporter
expression data from unmanaged, or poorly managed, diabetes
is unavailable, the true effect size is currently unknown.
Figure 3. Placental ABC efflux transporter expression in pregnancies complicated by insulin-managed diabetes. A, MDR1 (ABCB1). B,
MRP2 (ABCC2). C, BCRP (ABCG2). Boxes represent quartiles enclosing 50% of the data and the whiskers at either end extend to the 25
th and 75
th
quartiles. The median is marked by a line, the mean is marked by an ‘‘+’’ and outliers are marked by a ‘‘N’’ outside the 25
th and 75
th quartiles. The
‘‘Combined’’ group presents data from all patients (n=33) and was not included in statistical analyses. D, Spearman correlation analysis of the
relationship between HbA1c levels (%) and BCRP protein expression in diabetic pregnancies (p,0.05).
doi:10.1371/journal.pone.0035027.g003
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typically more variable than data obtained in animal models. The
overall coefficient of variation, a measure of variation about the
mean, for MDR1, MRP2 and BCRP protein expression in this
study was found to be 71%, 61% and 54%, respectively. This is
consistent with our animal model data [16] and comparable to
other studies of transporter expression in human term placenta
[20,51]. Interestingly, interindividual transporter expression var-
iation, as demonstrated in this study, appears to be small in
comparison to other tissues. For example, 55-fold, 20.5-fold and
20-fold variation in human hepatic MDR1 has been observed
[52,53,54]. Similarly, there are reports of 6-fold and 3-fold
variation in human intestinal MDR1 [55,56].
The strengths of our study lie in the novelty of our findings
given that placental transporter expression in GDM-I and T1DM-
I has yet to be investigated in a clinically relevant population. Also,
our retrospective design allowed for ‘‘real-world’’ results allowing
for the possibility of patient non-adherence in their insulin dosage
regimens. It is highly plausible that in a true prospective research
design where clinical data were collected over time, we may not
have observed any such effect due to the ethical requirements of
medical staff to recommend changes in insulin dosing or to
administer a therapeutic alternative to insulin (e.g., oral hyopo-
glycemics) to help better manage blood glucose in non-adherent
patients.
Despite the strength of our retrospective BioBank design, there
were some limitations to our work. Firstly, the RCWIH BioBank
was only able to extract information contained within the patient
charts of donors to the BioBank program. This resulted in a lack
of all possible clinical data (e.g., lipid profiling) that could have
shed additional light on our patient populations. Also, despite
observing significant correlations in our groups with the number
of samples that were available, additional samples could have
been added to further increase the power and magnitude of our
study’s findings. Lastly, the fact that HbA1c levels were not
available for our term-matched control patients is a limitation of
our study but, clinically, an HbA1c assay is not typically ordered
for patients with no history of glucose mismanagement. Samples
from pregnancies with documented mismanagement of blood
glucose were unavailable.
In conclusion, there are two particularly important aspects of
this study. First, it suggests that placental transporter expression in
well-managed T1DM-I and a GDM-I pregnancy is not signifi-
cantly different from healthy term controls. However, this may not
hold true when hyperglycemia is unmanaged. Supporting this is
the observed significant correlation between HbA1c and BCRP
mRNA and protein in both insulin-managed diabetes groups.
Increased levels of HbA1c were associated with increased levels of
BCRP mRNA and protein and could have implications for
maternal-fetal disposition of clinically important therapeutics and
other xenobiotics. Admittedly, samples from pregnancies with
documented mismanagement of blood glucose were unavailable,
so it remains unknown if placental transporter expression is
normal in T1DM-I and GDM-I because of proper management
or because the human and rat placental response differs. Second,
this study provides evidence that interindividual variability in
placental transporter expression is comparatively less than that
observed in other tissues. This suggests that disease-induced
transporter expression changes may be easier to detect in the
placenta, as seen in the recent work by Mason et al [57]. Future
studies investigating the role of maternal disease in determining
placental transporter expression will allow for a better un-
derstanding of the disposition of drugs and other xenobiotics
during diseased-states in pregnancy.
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